Piper Sandler Reiterates Overweight on Sage Therapeutics, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi has reiterated an Overweight rating on Sage Therapeutics but has lowered the price target from $52 to $26.

October 30, 2024 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Sage Therapeutics but significantly reduced the price target from $52 to $26, indicating a more cautious outlook.
The reduction in the price target from $52 to $26 suggests a more cautious outlook on Sage Therapeutics' future performance, despite the Overweight rating being maintained. This could lead to a negative short-term impact on the stock price as investors may react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100